Clinical Trial Update: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating magrolimab plus azacitidine versus azacitidine plus placebo in untreated myelodysplastic syndrome (MDS) patients was terminated. Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Magrolimab (magrolimab)

Snippet

Sponsor: Gilead Sciences | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: TERMINATED | Results posted: 2024-03-21